CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas
Recommended Citation
Zhang S, Ozer BH, Omuro A, Yuan Y, Mendoza T, Wall K, Grajkowska E, Vera E, Reyes J, Aldape K, Penas-Prado M, Wu J, Burton EC, Walbert T, Mikkelsen T, Weathers SP, O'Brien B, de Groot J, Puduvalli V, DeAngelis L, Pentsova E, Kaley TJ, Gavrilovic I, Gerstner ER, Armstrong TS, Gilbert MR. CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas. Neurooncol Adv. 2026;8(1):vdag016.
Document Type
Article
Publication Date
3-9-2026
Publication Title
Neurooncol Adv
Abstract
BACKGROUND: Salvage therapies for adults with recurrent ependymoma are limited. A prior retrospective review of patients with recurrent ependymomas treated with bevacizumab and carboplatin reported a 75% radiographic response rate. This prospective single-arm, open-label Phase 2 study was designed to assess clinical efficacy of this regimen.
METHODS: Twenty-two patients were evaluated in this CERN Adult Clinical Trials network study. Adult patients (age ≥18) with recurrent ependymomas received carboplatin (AUC = 5-6) every 4 weeks and bevacizumab 10mg/kg every 2 weeks for 6 cycles, after which carboplatin was discontinued, while bevacizumab could be continued at physician's discretion. Imaging of areas involved and patient-reported outcomes (PRO) with the MD Anderson Symptom Inventory (brain and/or spine modules) were assessed at baseline and every 2 cycles.
RESULTS: With a median follow-up time of 25.9 months (mo), the primary endpoint of 12-mo progression-free survival rate (PFS-12) greater than 50% was reached, with a rate of 76.4% (95% CI, 52.2, 89.4). The median PFS of this cohort was 18.0 mo. Two patients achieved objective partial responses (9.1%). There were no treatment-related grade ≥4 toxicities. Brain tumor responders (radiographic objective response or stable disease) experienced improved cognitive and neurological symptoms, while spine tumor patients reported worsening symptom outcomes regardless of response.
CONCLUSIONS: Treatment with carboplatin and bevacizumab in adult recurrent ependymomas met the PFS-12 clinical efficacy endpoint. However, symptomatic worsening in spinal tumors suggests imaging stability and symptom improvement in brain disease may be related to bevacizumab pseudo-response.
PubMed ID
42016022
Volume
8
Issue
1
First Page
016
Last Page
016
